ALL Metrics
-
Views
-
Downloads
Get PDF
Get XML
Cite
Export
Track
Research Article

High prevalence of diabetes mellitus and impaired glucose tolerance in liver cancer patients: A hospital based study of 4610 patients with benign tumors or specific cancers

[version 1; peer review: 2 approved]
PUBLISHED 16 Jun 2016
Author details Author details
OPEN PEER REVIEW
REVIEWER STATUS

Abstract

Objective: The prevalence of diabetes mellitus (DM), impaired glucose tolerance (IGT) and impaired fasting glucose (IFG) were hypothesised to be different among different tumor patients. This study aimed to study the association between the prevalence of DM, IGT and IFG and liver cancer, colorectal cancer, breast cancer, cervical cancer, nasopharyngeal cancer and benign tumor.
Methods:  A hospital based retrospective study was conducted on 4610 patients admitted to the Internal Medical Department of the Affiliated Tumor Hospital of Guangxi Medical University, China. Logistic regression was used to examine the association between gender, age group, ethnicity , cancer types or benign tumors and prevalence of DM, IFG, IGT.
Results: Among 4610 patients, there were 1000 liver cancer patients, 373 breast cancer patients, 415 nasopharyngeal cancer patients, 230 cervical cancer patients, 405 colorectal cancer patients, and 2187 benign tumor patients. The prevalence of DM and IGT in liver cancer patients was 14.7% and 22.1%, respectively. The prevalence of DM and IGT was 13.8% and 20%, respectively, in colorectal cancer patients, significantly higher than that of benign cancers. After adjusting for gender, age group, and ethnicity, the prevalence of DM and IGT in liver cancers patients was 1.29 times (CI :1.12-1.66) and 1.49 times (CI :1.20-1.86) higher than that of benign tumors, respectively.
Conclusion: There was a high prevalence of DM and IGT in liver cancer patients.

Keywords

Prevalence, Diabetes mellitus, Impaired glucose tolerance, Liver cancer, Risk Factor

Background

High fat and carbohydrate diets, associated with dietary carcinogenesis, contribute to abnormal glucose tolerance and cancer1,2. Previous studies suggest that metabolic syndrome is associated with a modestly increased risk of second breast cancer events and breast cancer-specific mortality3. Blood glucose level in colorectal cancer patients has been shown to correlate significantly with local tumor malignancy4. Antidiabetic medication such as metformin treatment could significantly lower the risk of colorectal cancer in type 2 diabetes mellitus (T2DM) patients5. However, little is known on the correlation between prevalence of impaired glucose tolerance (IGT), diabetes mellitus (DM) and other types of cancers in comparison with benign tumors.

As an ethnic area, Guangxi Zhuang automonous region (abbreviated as Guangxi) located in southwest China, is well known for its high incidence of liver cancer and nasopharyngeal cancer6,7. Established risk factors including heavy alcohol consumption, chronic infection with the hepatitis B virus (HBV) or the hepatitis C virus (HCV), tobacco smoking, intake of aflatoxin-contaminated foods for the development of hepatocellular carcinoma (HCC) have been studied in Guangxi over the past several decades8. According to an American study, abnormal glucose tolerance was an independent predictor for cancer mortality9. Therefore, it is essential to investigate the prevalence of DM, IGT, and IFG (impaired fasting glucose) among patients with common types of cancer in such a high incidence area.

This study aimed to investigate the association between the prevalence of DM, IGT and IFG and liver cancer, colorectal cancer, breast cancer, cervical cancer, nasopharyngeal cancer and benign tumors.

Method

Data collection

This hospital based study was approved by the Medical Ethics Committee of the Affiliated Tumor Hospital of Guangxi Medical University, China. The data were retrieved from the Internal Medical Department of the hospital. All personal identification was encrypted.

Patients hospitalized in the Internal Medical Department between 2010 and 2012 with complete records of fasting plasma glucose (FPG) and 2-h postprandial glucose (2hPPG) upon hospitalization were included in this study. Clinical data were collected, including gender, age, ethnicity, DM history, diagnosis, pathological diagnosis, FPG, and 2hPPG. All diagnoses of cancers and benign tumors were based on CT scan results, endoscopic biopsy or surgical resection. Those who had serious cardiocelebral diseases, liver or kidney dysfunction and other conditions that may influence diabetic or prediabetic state were excluded from this study.

Measurement of glucose level

The glucose levels were included in the retrospective data. The 1999 World Health Organization (WHO) diagnostic criteria were used to diagnose DM, IFG and IGT10. Results of plasma glucose testing were categorized as follows. Normal glucose tolerance (NGT): FPG <6.1 mmol/L, and 2hPPG <7.8 mmol/L; Diabetes mellitus (DM): FPG ≥7 .0 mmol/L, 2hPPG ≥11.1 mmol/L, and with DM medical history. Impaired Fasting blood glucose (IFG): FPG ≥6.1 mmol/L and <7.0 mmol/L with the exclusion of cases with DM history or 2hPPG ≥11.1 mmol/L. Impaired glucose tolerance (IGT): FPG<7.0 mmol/L, and 2hPPG ≥7.8 mmol/L and <11.1 mmol/L with the exclusion of cases with DM history.

Statistical analysis

Descriptive data were presented as frequencies and percentages, followed by a chi-square test or Fisher’s test as appropriate. Logistic regression was used to examine the association between gender, age group, ethnicity and cancer types or benign tumors and prevalence of DM, IFG, IGT. Data analyses were performed using the R language and environment (version 3.1.0)11 and the Epicalc package (version 3.1.1.2)12.

Results

sexethnicdmhistFGpbgage.grDMIFGIGTdia1dia2dia3dia4dia5dia6dia7dia8Diagnosis
Malezhuangno5.535.5(50,60]FALSEFALSEFALSETRUEFALSEFALSEFALSETRUEFALSEFALSEFALSEliver cancer
Malehanno4.693.9(30,40]FALSEFALSEFALSETRUEFALSEFALSEFALSETRUEFALSEFALSEFALSEliver cancer
Malezhuangno5.014.63(30,40]FALSEFALSEFALSETRUEFALSEFALSEFALSETRUEFALSEFALSEFALSEliver cancer
Malezhuangno4.84.43(30,40]FALSEFALSEFALSETRUEFALSEFALSEFALSETRUEFALSEFALSEFALSEliver cancer
Malehanyes5.1712.41(50,60]TRUEFALSEFALSETRUEFALSEFALSEFALSETRUEFALSEFALSEFALSEliver cancer
Malehanno4.466.19(50,60]FALSEFALSEFALSETRUEFALSEFALSEFALSETRUEFALSEFALSEFALSEliver cancer
Malehanno3.13.9(60,70]FALSEFALSEFALSETRUEFALSEFALSEFALSETRUEFALSEFALSEFALSEliver cancer
Malehanno3.764.47(30,40]FALSEFALSEFALSETRUEFALSEFALSEFALSETRUEFALSEFALSEFALSEliver cancer
Malehanyes6.7714.18(50,60]TRUEFALSEFALSETRUEFALSEFALSEFALSETRUEFALSEFALSEFALSEliver cancer
Malehanno12.9216.2(60,70]TRUEFALSEFALSETRUEFALSEFALSEFALSETRUEFALSEFALSEFALSEliver cancer
Malezhuangno5.944.82(40,50]FALSEFALSEFALSETRUEFALSEFALSEFALSETRUEFALSEFALSEFALSEliver cancer
Malehanno4.729.47(50,60]FALSEFALSETRUETRUEFALSEFALSEFALSETRUEFALSEFALSEFALSEliver cancer
Malezhuangno5.455.7(50,60]FALSEFALSEFALSETRUEFALSEFALSEFALSETRUEFALSEFALSEFALSEliver cancer
Femalehanno4.475.2(30,40]FALSEFALSEFALSETRUEFALSEFALSEFALSETRUEFALSEFALSEFALSEliver cancer
Malehanno5.338.4(50,60]FALSEFALSETRUETRUEFALSEFALSEFALSETRUEFALSEFALSEFALSEliver cancer
Malezhuangno3.765.65(50,60]FALSEFALSEFALSETRUEFALSEFALSEFALSETRUEFALSEFALSEFALSEliver cancer
Malehanno5.365.63(40,50]FALSEFALSEFALSETRUEFALSEFALSEFALSETRUEFALSEFALSEFALSEliver cancer
Femalehanno7.0911.74(70,100]TRUEFALSEFALSETRUEFALSEFALSEFALSETRUEFALSEFALSEFALSEliver cancer
Malezhuangno5.449.57(40,50]FALSEFALSETRUETRUEFALSEFALSEFALSETRUEFALSEFALSEFALSEliver cancer
Malehanno6.8716.34(70,100]TRUEFALSEFALSETRUEFALSEFALSEFALSETRUEFALSEFALSEFALSEliver cancer
Malezhuangno3.624.36(40,50]FALSEFALSEFALSETRUEFALSEFALSEFALSETRUEFALSEFALSEFALSEliver cancer
Malehanno3.14.52(40,50]FALSEFALSEFALSETRUEFALSEFALSEFALSETRUEFALSEFALSEFALSEliver cancer
Malehanno4.164.68(50,60]FALSEFALSEFALSETRUEFALSEFALSEFALSETRUEFALSEFALSEFALSEliver cancer
Malezhuangno5.57.44(40,50]FALSEFALSEFALSETRUEFALSEFALSEFALSETRUEFALSEFALSEFALSEliver cancer
Malezhuangno4.773.95(0,30]FALSEFALSEFALSETRUEFALSEFALSEFALSETRUEFALSEFALSEFALSEliver cancer
Femalehanno4.694.2(50,60]FALSEFALSEFALSETRUEFALSEFALSEFALSETRUEFALSEFALSEFALSEliver cancer
Malezhuangno3.823.9(40,50]FALSEFALSEFALSETRUEFALSEFALSEFALSETRUEFALSEFALSEFALSEliver cancer
Femalehanno3.819.41(40,50]FALSEFALSETRUETRUEFALSEFALSEFALSETRUEFALSEFALSEFALSEliver cancer
Malezhuangno3.784.24(40,50]FALSEFALSEFALSETRUEFALSEFALSEFALSETRUEFALSEFALSEFALSEliver cancer
Malehanno3.514.49(40,50]FALSEFALSEFALSETRUEFALSEFALSEFALSETRUEFALSEFALSEFALSEliver cancer
Malehanno4.674.71(50,60]FALSEFALSEFALSETRUEFALSEFALSEFALSETRUEFALSEFALSEFALSEliver cancer
Malehanno4.445.8(40,50]FALSEFALSEFALSETRUEFALSEFALSEFALSETRUEFALSEFALSEFALSEliver cancer
Malehanno5.0216.6(50,60]TRUEFALSEFALSETRUEFALSEFALSEFALSETRUEFALSEFALSEFALSEliver cancer
Malezhuangno4.916.5(70,100]FALSEFALSEFALSETRUEFALSEFALSEFALSETRUEFALSEFALSEFALSEliver cancer
Malehanno3.545(50,60]FALSEFALSEFALSETRUEFALSEFALSEFALSETRUEFALSEFALSEFALSEliver cancer
Malehanno3.975.98(50,60]FALSEFALSEFALSETRUEFALSEFALSEFALSETRUEFALSEFALSEFALSEliver cancer
Femalehanno5.6510.78(70,100]FALSEFALSETRUETRUEFALSEFALSEFALSETRUEFALSEFALSEFALSEliver cancer
Malehanyes7.1912.47(60,70]TRUEFALSEFALSETRUEFALSEFALSEFALSETRUEFALSEFALSEFALSEliver cancer
Malezhuangno4.733.69(50,60]FALSEFALSEFALSETRUEFALSEFALSEFALSETRUEFALSEFALSEFALSEliver cancer
Malehanno5.26.59(40,50]FALSEFALSEFALSETRUEFALSEFALSEFALSETRUEFALSEFALSEFALSEliver cancer
Malehanno5.47.79(50,60]FALSEFALSEFALSETRUEFALSEFALSEFALSETRUEFALSEFALSEFALSEliver cancer
Malehanno4.926.67(50,60]FALSEFALSEFALSETRUEFALSEFALSEFALSETRUEFALSEFALSEFALSEliver cancer
Malehanno4.738.71(40,50]FALSEFALSETRUETRUEFALSEFALSEFALSETRUEFALSEFALSEFALSEliver cancer
Malezhuangno3.988.18(30,40]FALSEFALSETRUETRUEFALSEFALSEFALSETRUEFALSEFALSEFALSEliver cancer
Malehanno4.215.1(40,50]FALSEFALSEFALSETRUEFALSEFALSEFALSETRUEFALSEFALSEFALSEliver cancer
Malehanno4.8910.49(50,60]FALSEFALSETRUETRUEFALSEFALSEFALSETRUEFALSEFALSEFALSEliver cancer
Femalehanno4.224.2(40,50]FALSEFALSEFALSETRUEFALSEFALSEFALSETRUEFALSEFALSEFALSEliver cancer
Malezhuangno3.14.3(50,60]FALSEFALSEFALSETRUEFALSEFALSEFALSETRUEFALSEFALSEFALSEliver cancer
Malezhuangno4.627.84(60,70]FALSEFALSETRUETRUEFALSEFALSEFALSETRUEFALSEFALSEFALSEliver cancer
Malezhuangno3.95.92(60,70]FALSEFALSEFALSETRUEFALSEFALSEFALSETRUEFALSEFALSEFALSEliver cancer
Malehanno4.646.6(40,50]FALSEFALSEFALSETRUEFALSEFALSEFALSETRUEFALSEFALSEFALSEliver cancer
Malezhuangno4.634.03(0,30]FALSEFALSEFALSETRUEFALSEFALSEFALSETRUEFALSEFALSEFALSEliver cancer
Malehanno2.46.56(50,60]FALSEFALSEFALSETRUEFALSEFALSEFALSETRUEFALSEFALSEFALSEliver cancer
Malehanno4.975.78(60,70]FALSEFALSEFALSETRUEFALSEFALSEFALSETRUEFALSEFALSEFALSEliver cancer
Malehanno5.296.81(50,60]FALSEFALSEFALSETRUEFALSEFALSEFALSETRUEFALSEFALSEFALSEliver cancer
Malehanno4.648.12(50,60]FALSEFALSETRUETRUEFALSEFALSEFALSETRUEFALSEFALSEFALSEliver cancer
Malezhuangno5.148.12(70,100]FALSEFALSETRUETRUEFALSEFALSEFALSETRUEFALSEFALSEFALSEliver cancer
Malehanno4.677.58(40,50]FALSEFALSEFALSETRUEFALSEFALSEFALSETRUEFALSEFALSEFALSEliver cancer
Malehanno4.725.16(40,50]FALSEFALSEFALSETRUEFALSEFALSEFALSETRUEFALSEFALSEFALSEliver cancer
Malehanno3.584.67(30,40]FALSEFALSEFALSETRUEFALSEFALSEFALSETRUEFALSEFALSEFALSEliver cancer
Malehanno5.114.39(40,50]FALSEFALSEFALSETRUEFALSEFALSEFALSETRUEFALSEFALSEFALSEliver cancer
Malehanno5.479.22(50,60]FALSEFALSETRUETRUEFALSEFALSEFALSETRUEFALSEFALSEFALSEliver cancer
Malehanno6.5610.73(40,50]FALSETRUETRUETRUEFALSEFALSEFALSETRUEFALSEFALSEFALSEliver cancer
Malehanyes14.7525.87(70,100]TRUEFALSEFALSETRUEFALSEFALSEFALSETRUEFALSEFALSEFALSEliver cancer
Malehanno6.44.82(70,100]FALSETRUEFALSETRUEFALSEFALSEFALSETRUEFALSEFALSEFALSEliver cancer
Malehanno5.225.55(40,50]FALSEFALSEFALSETRUEFALSEFALSEFALSETRUEFALSEFALSEFALSEliver cancer
Malehanno6.325.16(70,100]FALSETRUEFALSETRUEFALSEFALSEFALSETRUEFALSEFALSEFALSEliver cancer
Malehanno5.144.44(40,50]FALSEFALSEFALSETRUEFALSEFALSEFALSETRUEFALSEFALSEFALSEliver cancer
Malehanno5.8211.86(40,50]TRUEFALSEFALSETRUEFALSEFALSEFALSETRUEFALSEFALSEFALSEliver cancer
Malezhuangno5.1610.69(40,50]FALSEFALSETRUETRUEFALSEFALSEFALSETRUEFALSEFALSEFALSEliver cancer
Malezhuangno4.164.77(40,50]FALSEFALSEFALSETRUEFALSEFALSEFALSETRUEFALSEFALSEFALSEliver cancer
Femalezhuangno4.155.5(60,70]FALSEFALSEFALSETRUEFALSEFALSEFALSETRUEFALSEFALSEFALSEliver cancer
Malehanno4.599.31(40,50]FALSEFALSETRUETRUEFALSEFALSEFALSETRUEFALSEFALSEFALSEliver cancer
Malezhuangno4.717.01(40,50]FALSEFALSEFALSETRUEFALSEFALSEFALSETRUEFALSEFALSEFALSEliver cancer
Maleother ethnicno4.974.74(40,50]FALSEFALSEFALSETRUEFALSEFALSEFALSETRUEFALSEFALSEFALSEliver cancer
Malehanno4.166.44(30,40]FALSEFALSEFALSETRUEFALSEFALSEFALSETRUEFALSEFALSEFALSEliver cancer
Femalehanno6.026.29(50,60]FALSEFALSEFALSETRUEFALSEFALSEFALSETRUEFALSEFALSEFALSEliver cancer
Malehanno4.976.67(40,50]FALSEFALSEFALSETRUEFALSEFALSEFALSETRUEFALSEFALSEFALSEliver cancer
Femalezhuangno5.16.68(50,60]FALSEFALSEFALSETRUEFALSEFALSEFALSETRUEFALSEFALSEFALSEliver cancer
Malehanno3.8912.26(40,50]TRUEFALSEFALSETRUEFALSEFALSEFALSETRUEFALSEFALSEFALSEliver cancer
Malehanno5.393.97(50,60]FALSEFALSEFALSETRUEFALSEFALSEFALSETRUEFALSEFALSEFALSEliver cancer
Malehanno5.245(60,70]FALSEFALSEFALSETRUEFALSEFALSEFALSETRUEFALSEFALSEFALSEliver cancer
Malezhuangno4.76.65(0,30]FALSEFALSEFALSETRUEFALSEFALSEFALSETRUEFALSEFALSEFALSEliver cancer
Malezhuangno5.915.45(30,40]FALSEFALSEFALSETRUEFALSEFALSEFALSETRUEFALSEFALSEFALSEliver cancer
Malehanno6.384.76(40,50]FALSETRUEFALSETRUEFALSEFALSEFALSETRUEFALSEFALSEFALSEliver cancer
Malehanno5.1512.54(50,60]TRUEFALSEFALSETRUEFALSEFALSEFALSETRUEFALSEFALSEFALSEliver cancer
Malehanno5.167.57(40,50]FALSEFALSEFALSETRUEFALSEFALSEFALSETRUEFALSEFALSEFALSEliver cancer
Malehanno4.397.2(40,50]FALSEFALSEFALSETRUEFALSEFALSEFALSETRUEFALSEFALSEFALSEliver cancer
Malezhuangno5.067.26(40,50]FALSEFALSEFALSETRUEFALSEFALSEFALSETRUEFALSEFALSEFALSEliver cancer
Malezhuangno5.779.29(40,50]FALSEFALSETRUETRUEFALSEFALSEFALSETRUEFALSEFALSEFALSEliver cancer
Malehanyes6.917.57(50,60]TRUEFALSEFALSETRUEFALSEFALSEFALSETRUEFALSEFALSEFALSEliver cancer
Malehanno7.8120.87(40,50]TRUEFALSEFALSETRUEFALSEFALSEFALSETRUEFALSEFALSEFALSEliver cancer
Malehanno4.045.12(30,40]FALSEFALSEFALSETRUEFALSEFALSEFALSETRUEFALSEFALSEFALSEliver cancer
Malehanno4.356.43(40,50]FALSEFALSEFALSETRUEFALSEFALSEFALSETRUEFALSEFALSEFALSEliver cancer
Malehanno4.969.99(40,50]FALSEFALSETRUETRUEFALSEFALSEFALSETRUEFALSEFALSEFALSEliver cancer
Maleother ethnicno4.647.56(40,50]FALSEFALSEFALSETRUEFALSEFALSEFALSETRUEFALSEFALSEFALSEliver cancer
Malehanyes5.3224.14(50,60]TRUEFALSEFALSETRUEFALSEFALSEFALSETRUEFALSEFALSEFALSEliver cancer
Malehanyes7.1615.72(70,100]TRUEFALSEFALSETRUEFALSEFALSEFALSETRUEFALSEFALSEFALSEliver cancer
Malehanno5.556.87(70,100]FALSEFALSEFALSETRUEFALSEFALSEFALSETRUEFALSEFALSEFALSEliver cancer
This is a portion of the data; to view all the data, please download the file.
Dataset 1.Patient data.
Dataset 2.Data analysis using R.

1. Demographic description and prevalence of DM, IGT, and IFG among different cancers and benign tumors:

A total of 4610 patients were included in this study. Figure 1 and Table 1 summarize the demographic characteristics of the patients, among whom 1000 were liver cancer patients, 373 breast cancer patients, 415 nasopharyngeal cancer patients, 230 cervical cancer patients, 405 colorectal cancer patients, and 2187 benign tumor patients. The patients in the 40–60 year age group comprised more than 50% of the total patients studied. Liver cancer, nasopharyngeal cancer, and colorectal cancer patients were predominantly male. Age and ethnic distribution among the studied groups were statistically different (P<0.001).

Table 1. Demographic information and prevalence of DM, IFG, and IGT among patients with specific cancers or benign tumors.

Liver cancer
(N=1000)
Breast cancer
(N=373)
Nasopharyngeal
cancer (N=415)
Cervical
cancer (N=230)
Colorectal
cancer (N=405)
Benign tumors
(N=2187)
Gender***
    Male878 (87.8)0(0.0)294 (70.8)0(0.0)255 (63.0)834 (38.1)
    Female122 (12.2)373(100.0)121 (29.2)230(100.0)150 (37.0)1353 (61.9)
Age
(median,IQR)***
49 (42,58)48 (40,56)46 (39,54)48 (42,55)59 (48,68)46 (36,57)
Ethnic groups***
    Han607 (60.7)256 (68.6)289 (69.6)153 (66.5)305 (75.3)1438 (66.8)
    other ethnicity20 (2.0)12 (3.2)6 (1.4)9 (3.9)10 (2.5)66 (3.1)
    Zhuang373 (37.3)105 (28.2)120 (28.9)68 (29.6)90 (22.2)650 (30.2)
DM***147 (14.7)39 (10.5)21 (5.1)18 (7.8)56 (13.8)197 (9.1)
IFG**28 (2.8)27 (7.2)25 (6.0)6 (2.6)22 (5.4)98 (4.5)
IGT***221 (22.1)48 (12.9)53 (12.8)28 (12.2)81 (20.0)262 (12.0)

Data were given as n (%). * p-value<0.05; ** p-value<0.01; *** p-value < 0.001.

15b55ae5-abec-4ffa-a62a-65d0014a1108_figure1.gif

Figure 1. Population pyramid distribution by gender and age group.

The prevalence of DM and IGT in liver cancer patients was 14.7% and 22.1%, respectively; 13.8% and 20% in colorectal cancer patients, which were significantly higher than that of benign cancers.

2. Association between prevalence of DM and cancer types and benign tumors

As shown in Table 2, adjusted for gender, ethnicity, and age group, the prevalence of DM in liver cancers patients was 1.29 times higher than that of benign tumors; male patients were 1.49 times of higher than that of female patients. Using the 0–30 year as reference, the prevalence of DM increased with age. The peak risk ratio was 10.3 times higher in the 61–70 year age group than that of 0–30 year age group. The Han ethnic group was 1.38 times more likely to have DM in comparison with the Zhuang ethnic group.

Table 2. Association between prevalence of DM and specific cancers or benign tumors.

crude OR(95%CI)adj. OR(95%CI)P(LR-test)
Diagnosis: ref.=benign tumor< 0.001
    Breast cancer1.17 (0.81,1.68)1.28 (0.87,1.89)
    Cervical tumor0.85 (0.51,1.4)0.88 (0.52,1.48)
    Colorector cancer1.6 (1.17,2.2)0.95 (0.69,1.33)
    Liver cancer1.72 (1.37,2.16)1.29 (1.12,1.66)
    Nasopharyngeal cancer0.53 (0.34,0.85)0.46 (0.29,0.74)
Gender: male vs female1.74 (1.44,2.12)1.49 (1.17,1.89)0.001
Ethnicity: ref.=Zhuang0.018
    Han1.47 (1.18,1.83)1.38 (1.1,1.74)
    Other ethnicity1.34 (0.73,2.45)1.36 (0.73,2.53)
Age group: ref.=(0,30)< 0.001
    (31,40)1.88 (0.9,3.97)1.87 (0.89,3.95)
    (41,50)3.9 (1.96,7.79)3.75 (1.87,7.52)
    (51,60)8.94 (4.53,17.66)8.14 (4.1,16.17)
    (61,70)11.36 (5.69,22.69)10.3 (5.13,20.68)
    >708.46 (4.09,17.54)7.28 (3.49,15.18)

3. Association between prevalence of IGT and cancer types and benign tumors

As shown in Table 3, adjusted for gender, ethnicity, and age group, the prevalence of IGT in liver cancer patients was 1.49 times higher than that of benign tumors; male patients were 1.71 times higher than that of female patients. Using the 0–30 year as reference, there were an obvious age-dependent relationship between age groups and prevalence of IGT. There were no significant difference among the ethnic groups in terms of IGT prevalence (P=0.421).

Table 3. Association between prevalence of IGT and specific cancers or benign tumors.

crude OR(95%CI)adj. OR(95%CI)P(LR-test)
Diagnosis: ref.=benign tumors0.002
    Breast cancer1.07 (0.77,1.48)1.28 (0.9,1.82)
    Cervical tumor1 (0.66,1.52)1.17 (0.76,1.8)
    Colorector cancer1.81 (1.37,2.38)1.25 (0.94,1.67)
    Liver cancer2.05 (1.68,2.5)1.49 (1.2,1.86)
    Nasopharyngeal cancer1.06 (0.77,1.45)0.88 (0.64,1.22)
Gender: male vs female2.01 (1.7,2.38)1.71 (1.39,2.1)< 0.001
Ethnicity: ref.=Zhuang0.421
    Han1.07 (0.9,1.28)1.04 (0.86,1.24)
    Other ethnicity0.69 (0.38,1.25)0.71 (0.39,1.3)
Age group: ref.=(0,30)< 0.001
    (31,40)1.66 (1.06,2.6)1.55 (0.98,2.43)
    (41,50)2.63 (1.73,3.99)2.34 (1.53,3.58)
    (51,60)3.18 (2.09,4.84)2.67 (1.74,4.09)
    (61,70)3.83 (2.47,5.94)3.19 (2.04,4.98)
    >704.62 (2.89,7.38)3.79 (2.35,6.12)

4. Association between prevalence of IFG and cancer types and benign tumors

As shown in Table 4, adjusted for gender, ethnicity, and age group, the prevalence of IFG in liver cancers patients was 0.55 times lower than that of benign tumors. Using the 0–30 year as reference, the prevalence of IFG increased with age. The Han ethnic group was 1.59 times higher in prevalence of IFG in comparison with the Zhuang ethnic group.

Table 4. Association between prevalence of IFG and specific cancers or benign tumors.

crude OR(95%CI)adj. OR(95%CI)P(LR-test)
Diagnosis: ref.=benign tumor0.003
    Breast cancer1.64 (1.05,2.54)1.57 (0.99,2.51)
    Cervical tumor0.56 (0.24,1.3)0.53 (0.23,1.24)
    Colorector cancer1.21 (0.75,1.94)0.92 (0.57,1.51)
    Liver cancer0.6 (0.39,0.93)0.55 (0.35,0.87)
    Nasopharyngeal cancer1.34 (0.86,2.11)1.26 (0.79,2.02)
Gender: Male vs Female0.96 (0.73,1.27)1.08 (0.77,1.52)0.641
Ethnicity: ref.=Zhuang0.023
    Han1.73 (1.23,2.44)1.59 (1.13,2.26)
    Other ethnicity1.34 (0.52,3.46)1.25 (0.48,3.24)
Age group: ref.=(0,30)< 0.001
    (31,40)1.99 (0.86,4.59)2.06 (0.89,4.78)
    (41,50)3.19 (1.45,7)3.35 (1.52,7.41)
    (51,60)2.97 (1.34,6.61)3.13 (1.4,7.03)
    (61,70)3.34 (1.45,7.67)3.46 (1.49,8.01)
    >705.01 (2.13,11.78)4.89 (2.06,11.65)

Discussion

This study showed that the prevalence of DM and IGT in liver cancer patients was 14.7% and 22.1%, respectively. After adjustment for gender, age group, and ethnicity, the prevalence of DM and IGT in liver cancer patients was 1.29 times (CI :1.12–1.66) and 1.49 times (CI :1.20–1.86) higher, respectively, than that of benign tumors. In comparison, the prevalence of DM and IGT in patients with breast cancer, cervical cancer, colorectal cancer, and nasopharyngeal cancer was not significantly different from that of benign tumors after adjusted for gender, age group, and ethnicity.

A previous study suggested high blood glucose levels in colorectal cancer patients with larger tumor diameters and lower tumor differentiation4. Our study also found that the prevalence of DM and IGT was high in colorectal cancer patients in the preliminary analysis, although no statistical difference was found after adjustments for other factors. So far, there have been very few studies on the relationship between prevalence of DM and IGT and liver cancer. However, the relationship between obesity, overweight and higher rates of death due to cancer of esophagus, colon, rectum, liver, gallbladder, pancreas and kidney, non-Hodgkin’s lymphoma, and multiple myeloma has been well established by a large sample prospective study13. The reason why a high prevalence of DM and IGT is correlated with liver cancer may be explained as follows: As a regulator of energy storage and metabolism, insulin was produced and secreted by pancreatic β cells, which stimulated glucose uptake by adipose tissue and muscle, suppressing the release of glucose from the liver. Desensitization of tissues to insulin and insulin resistance led to a compensating increase in pancreatic insulin production called hyperinsulinemia, which may have possible direct oncogenic effects on proliferative and anti-apoptosis signaling in cancer cells.

High prevalence of DM and IGT correlated with liver cancer had important implications both in prevention and treatment of liver cancer. Metformin, a commonly used drug for type 2 diabetes, led to a lower incidence and mortality of breast cancer1418. In a similar way, the control of high blood glucose levels would possibly improve clinical outcomes of liver cancer patients.

Strengths and limitations

As a hospital based study recently conducted in Guangxi with a high incidence of liver cancers, this study provided evidence for government and public health planners which may be useful in the prevention of liver cancer. Further prospective cohort studies should be conducted to learn the strength of association between DM, IGT and liver cancer; moreover, to learn how much the control of diabetic or pre-diabetic conditions contributes to the prevention and treatment of liver cancer.

Conclusion

This study showed a high prevalence of DM and IGT in liver cancer patients. The control of diabetic or pre-diabetic conditions may contribute to the prevention and treatment of liver cancer.

Data and software availability

F1000Research: Dataset 1. Patient data, 10.5256/f1000research.8457.d12289419

F1000Research: Dataset 2. Data analysis using R, 10.5256/f1000research.8457.d12289520

Comments on this article Comments (0)

Version 1
VERSION 1 PUBLISHED 16 Jun 2016
Comment
Author details Author details
Competing interests
Grant information
Copyright
Download
 
Export To
metrics
Views Downloads
F1000Research - -
PubMed Central
Data from PMC are received and updated monthly.
- -
Citations
CITE
how to cite this article
Roujun C, Yanhua Y and Bixun L. High prevalence of diabetes mellitus and impaired glucose tolerance in liver cancer patients: A hospital based study of 4610 patients with benign tumors or specific cancers [version 1; peer review: 2 approved]. F1000Research 2016, 5:1397 (https://doi.org/10.12688/f1000research.8457.1)
NOTE: If applicable, it is important to ensure the information in square brackets after the title is included in all citations of this article.
track
receive updates on this article
Track an article to receive email alerts on any updates to this article.

Open Peer Review

Current Reviewer Status: ?
Key to Reviewer Statuses VIEW
ApprovedThe paper is scientifically sound in its current form and only minor, if any, improvements are suggested
Approved with reservations A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit.
Not approvedFundamental flaws in the paper seriously undermine the findings and conclusions
Version 1
VERSION 1
PUBLISHED 16 Jun 2016
Views
15
Cite
Reviewer Report 23 Aug 2016
Nirun Intarut, Clinical Epidemiology Unit, Faculty of Medicine, Mahasarakham University, Maha Sarakham, Thailand 
Approved
VIEWS 15
This is a retrospective study that was carried out in a hospital in China, involving 4610 participants. In summary, this study investigated the association between the DM, IGT and IFG and liver cancer, colorectal cancer, breast cancer, cervical cancer, nasopharyngeal ... Continue reading
CITE
CITE
HOW TO CITE THIS REPORT
Intarut N. Reviewer Report For: High prevalence of diabetes mellitus and impaired glucose tolerance in liver cancer patients: A hospital based study of 4610 patients with benign tumors or specific cancers [version 1; peer review: 2 approved]. F1000Research 2016, 5:1397 (https://doi.org/10.5256/f1000research.9106.r14411)
NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article.
Views
27
Cite
Reviewer Report 24 Jun 2016
He Jianhui, Department of Health Economics and Health Management, Kunming Medical University, Kunming, China 
Approved
VIEWS 27
The article entitled “High prevalence of diabetes mellitus and impaired glucose tolerance in liver cancer patients: A hospital based study of 4610 patients with benign tumors or specific cancers” is very meaningful on providing evidence for government to prevent liver cancer ... Continue reading
CITE
CITE
HOW TO CITE THIS REPORT
Jianhui H. Reviewer Report For: High prevalence of diabetes mellitus and impaired glucose tolerance in liver cancer patients: A hospital based study of 4610 patients with benign tumors or specific cancers [version 1; peer review: 2 approved]. F1000Research 2016, 5:1397 (https://doi.org/10.5256/f1000research.9106.r14413)
NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article.

Comments on this article Comments (0)

Version 1
VERSION 1 PUBLISHED 16 Jun 2016
Comment
Alongside their report, reviewers assign a status to the article:
Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested
Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit.
Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions
Sign In
If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password.

The email address should be the one you originally registered with F1000.

Email address not valid, please try again

You registered with F1000 via Google, so we cannot reset your password.

To sign in, please click here.

If you still need help with your Google account password, please click here.

You registered with F1000 via Facebook, so we cannot reset your password.

To sign in, please click here.

If you still need help with your Facebook account password, please click here.

Code not correct, please try again
Email us for further assistance.
Server error, please try again.